Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,816.89
(
-0.11%
)
US TECH 100
24,499.60
(
0.38%
)
Dow Jones
47,916.57
(
-0.56%
)
Brent Oil
92.41
(
0.00%
)
Bitcoin
72,723.23
(
-0.35%
)
News Focus
News Focus
Post# of 447259
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

ziploc_1

Send PM Follow Ignore
Followers 64
Posts 7748
Boards Moderated 1
Alias Born 01/02/2003

ziploc_1

Re: HinduKush post# 297347

Tuesday, 09/08/2020 12:10:55 PM

Tuesday, September 08, 2020 12:10:55 PM

Post# of 447259
Everyone involved, including Doctors,lawyers, pharmacists, patients, and judges are well aware that the Generics' strategy is to, by virtue of their skinny Marine label, infringe on the Reduce-It label by having Vascepa prescribed for patients, who are meant to utilize Vascepa...not for triglycerides over 500mgm/dcl.,but for the more profitable Reduce-It CVD indications...I don't think anyone can argue with a straight face that this is not the Generics' strategy to infringe on Amarin's patents
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent AMRN News
More AMRN News